
Opinion|Videos|November 8, 2024
From Guidelines to Practice: Advancing Lupus Nephritis Treatment
Author(s)Amit Saxena, MD
Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In your view, why are guidelines for lupus nephritis important to patient care?
- What role do the American College of Rheumatology (ACR) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines play in shaping treatment practices for lupus nephritis?
- What are some of the most significant recent changes in lupus nephritis guidelines?
- How has the treatment approach for lupus nephritis evolved in recent years alongside these guidelines?
Advertisement
Related to this article

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5


